Rate My Professor Philip Newsome

Professor Newsome’s research focuses on the role of cell therapy in liver injury, NAFLD now termed metabolic dysfunction-associated steatotic liver disease (MASLD), GLP-1 therapies, haematopoietic stem cell therapy in liver cirrhosis, and mesenchymal stromal cells in primary sclerosing cholangitis. He developed the FAST score for identifying at-risk NASH patients and co-led the global nomenclature change from NAFLD to MASLD. As Chief Investigator, he led randomised controlled trials of GLP-1 therapies in NAFLD published in The Lancet and The New England Journal of Medicine, the REALISTIC trial of haematopoietic stem cell therapy in liver cirrhosis published in Lancet Gastroenterology & Hepatology, and coordinates the MERLIN EU FP7 consortium trial of mesenchymal stromal cells in PSC. He chaired national guidelines for liver transplantation in NAFLD, sat on the NICE Guideline Development Group for NAFLD, led the UK multi-stakeholder guideline on abnormal liver blood tests, and contributed to the EASL–Lancet Liver Commission. He completed a term as Secretary General (President) of the European Association for the Study of the Liver, serves as National Clinical Lead for Advanced Therapy Treatment Centres, and is Senior Editor at the Journal of Hepatology. His awards include election as Fellow of the Academy of Medical Sciences and NIHR Senior Investigator (2024-2027). Key publications include 'A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis' (NEJM, 2024), 'The EASL–Lancet Liver Commission' (The Lancet, 2022), and 'Prognostic performance of the two-step clinical care pathway in metabolic dysfunction-associated steatotic liver disease' (Journal of Hepatology, 2025).